Omega Therapeutics Past Earnings Performance
Past criteria checks 0/6
Omega Therapeutics's earnings have been declining at an average annual rate of -22.4%, while the Biotechs industry saw earnings growing at 19.1% annually. Revenues have been growing at an average rate of 76.6% per year.
Key information
-22.4%
Earnings growth rate
43.8%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | 76.6% |
| Return on equity | -633.2% |
| Net Margin | -902.9% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Omega Therapeutics And Novo Nordisk Collaboration: A Cautious 'Buy'
Mar 31Is Omega Therapeutics (NASDAQ:OMGA) Weighed On By Its Debt Load?
Feb 28
Omega Therapeutics: The Next Weight Loss Drug Runner
Jan 16Omega Therapeutics: Starting 2024 With A Bang
Jan 10Omega Therapeutics GAAP EPS of -$0.54 in-line, revenue of $0.48M beats by $0.43M
Aug 04Omega Therapeutics gets FDA nod to start liver cancer trial of lead drug OTX-2002
Jul 14Revenue & Expenses Breakdown
How Omega Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 8 | -73 | 40 | 0 |
| 30 Jun 24 | 6 | -79 | 41 | 0 |
| 31 Mar 24 | 5 | -92 | 39 | 0 |
| 31 Dec 23 | 3 | -97 | 37 | 0 |
| 30 Sep 23 | 3 | -108 | 33 | 0 |
| 30 Jun 23 | 3 | -112 | 29 | 0 |
| 31 Mar 23 | 2 | -108 | 28 | 0 |
| 31 Dec 22 | 2 | -103 | 28 | 0 |
| 30 Sep 22 | 1 | -93 | 28 | 0 |
| 30 Jun 22 | 1 | -85 | 26 | 0 |
| 31 Mar 22 | 0 | -75 | 21 | 0 |
| 31 Dec 21 | 0 | -68 | 18 | 0 |
| 30 Sep 21 | 0 | -57 | 14 | -14 |
| 30 Jun 21 | 0 | -47 | 12 | -8 |
| 31 Mar 21 | 0 | -38 | 9 | -4 |
| 31 Dec 20 | 0 | -29 | 8 | 0 |
Quality Earnings: OMGA is currently unprofitable.
Growing Profit Margin: OMGA is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: OMGA is unprofitable, and losses have increased over the past 5 years at a rate of 22.4% per year.
Accelerating Growth: Unable to compare OMGA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: OMGA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).
Return on Equity
High ROE: OMGA has a negative Return on Equity (-633.21%), as it is currently unprofitable.